|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: WNT5B |
Gene summary for WNT5B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | WNT5B | Gene ID | 81029 |
| Gene name | Wnt family member 5B | |
| Gene Alias | WNT5B | |
| Cytomap | 12p13.33 | |
| Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | Q9H1J7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 81029 | WNT5B | CCI_2 | Human | Cervix | CC | 3.94e-13 | 1.16e+00 | 0.5249 |
| 81029 | WNT5B | CCI_3 | Human | Cervix | CC | 1.42e-15 | 9.06e-01 | 0.516 |
| 81029 | WNT5B | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.56e-03 | 1.34e-01 | 0.0155 |
| 81029 | WNT5B | HTA11_347_2000001011 | Human | Colorectum | AD | 1.75e-08 | 2.49e-01 | -0.1954 |
| 81029 | WNT5B | HTA11_411_2000001011 | Human | Colorectum | SER | 7.33e-04 | 6.06e-01 | -0.2602 |
| 81029 | WNT5B | HTA11_696_2000001011 | Human | Colorectum | AD | 1.93e-04 | 2.53e-01 | -0.1464 |
| 81029 | WNT5B | HTA11_99999965104_69814 | Human | Colorectum | MSS | 7.32e-04 | 2.76e-01 | 0.281 |
| 81029 | WNT5B | 048752_1579-all-cells | Human | Prostate | BPH | 1.19e-11 | 3.72e-01 | 0.1008 |
| 81029 | WNT5B | 052095_1628-all-cells | Human | Prostate | BPH | 4.61e-02 | 2.40e-01 | 0.1032 |
| 81029 | WNT5B | 052097_1595-all-cells | Human | Prostate | BPH | 2.56e-10 | 3.88e-01 | 0.0972 |
| 81029 | WNT5B | 052099_1652-all-cells | Human | Prostate | BPH | 9.98e-07 | 3.04e-01 | 0.1038 |
| 81029 | WNT5B | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 8.32e-08 | 5.24e-01 | 0.1633 |
| 81029 | WNT5B | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 3.29e-03 | 3.66e-01 | 0.1608 |
| 81029 | WNT5B | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 5.99e-06 | 4.72e-01 | 0.1621 |
| 81029 | WNT5B | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 8.55e-17 | 6.86e-01 | 0.1575 |
| 81029 | WNT5B | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 8.55e-06 | 4.07e-01 | 0.1545 |
| 81029 | WNT5B | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 4.39e-10 | 6.39e-01 | 0.1569 |
| 81029 | WNT5B | ATC12 | Human | Thyroid | ATC | 6.03e-40 | 8.20e-01 | 0.34 |
| 81029 | WNT5B | ATC13 | Human | Thyroid | ATC | 2.29e-02 | 9.08e-02 | 0.34 |
| 81029 | WNT5B | ATC2 | Human | Thyroid | ATC | 3.71e-05 | 5.34e-01 | 0.34 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
| GO:00160557 | Cervix | CC | Wnt signaling pathway | 98/2311 | 444/18723 | 4.82e-09 | 4.65e-07 | 98 |
| GO:01987387 | Cervix | CC | cell-cell signaling by wnt | 98/2311 | 446/18723 | 6.16e-09 | 5.58e-07 | 98 |
| GO:00301117 | Cervix | CC | regulation of Wnt signaling pathway | 76/2311 | 328/18723 | 3.05e-08 | 2.08e-06 | 76 |
| GO:00600707 | Cervix | CC | canonical Wnt signaling pathway | 66/2311 | 303/18723 | 2.47e-06 | 7.35e-05 | 66 |
| GO:00454445 | Cervix | CC | fat cell differentiation | 53/2311 | 229/18723 | 3.72e-06 | 9.75e-05 | 53 |
| GO:00073695 | Cervix | CC | gastrulation | 42/2311 | 185/18723 | 5.83e-05 | 8.46e-04 | 42 |
| GO:000206410 | Cervix | CC | epithelial cell development | 45/2311 | 220/18723 | 4.14e-04 | 4.21e-03 | 45 |
| GO:00301776 | Cervix | CC | positive regulation of Wnt signaling pathway | 31/2311 | 140/18723 | 8.01e-04 | 7.02e-03 | 31 |
| GO:00426924 | Cervix | CC | muscle cell differentiation | 69/2311 | 384/18723 | 8.12e-04 | 7.09e-03 | 69 |
| GO:0150063 | Cervix | CC | visual system development | 63/2311 | 375/18723 | 6.58e-03 | 3.65e-02 | 63 |
| GO:0001654 | Cervix | CC | eye development | 62/2311 | 371/18723 | 7.83e-03 | 4.13e-02 | 62 |
| GO:0048880 | Cervix | CC | sensory system development | 63/2311 | 381/18723 | 9.29e-03 | 4.66e-02 | 63 |
| GO:0002064 | Colorectum | AD | epithelial cell development | 89/3918 | 220/18723 | 2.98e-11 | 3.52e-09 | 89 |
| GO:0042060 | Colorectum | AD | wound healing | 128/3918 | 422/18723 | 2.73e-06 | 7.89e-05 | 128 |
| GO:0030111 | Colorectum | AD | regulation of Wnt signaling pathway | 102/3918 | 328/18723 | 8.51e-06 | 2.03e-04 | 102 |
| GO:0016055 | Colorectum | AD | Wnt signaling pathway | 130/3918 | 444/18723 | 1.60e-05 | 3.37e-04 | 130 |
| GO:0198738 | Colorectum | AD | cell-cell signaling by wnt | 130/3918 | 446/18723 | 2.02e-05 | 4.10e-04 | 130 |
| GO:0060070 | Colorectum | AD | canonical Wnt signaling pathway | 90/3918 | 303/18723 | 1.76e-04 | 2.38e-03 | 90 |
| GO:0030177 | Colorectum | AD | positive regulation of Wnt signaling pathway | 45/3918 | 140/18723 | 1.23e-03 | 1.09e-02 | 45 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501018 | Cervix | CC | Alzheimer disease | 113/1267 | 384/8465 | 9.67e-14 | 3.92e-12 | 2.32e-12 | 113 |
| hsa0502218 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
| hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
| hsa043609 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
| hsa051657 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
| hsa043109 | Cervix | CC | Wnt signaling pathway | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
| hsa043908 | Cervix | CC | Hippo signaling pathway | 40/1267 | 157/8465 | 3.64e-04 | 1.82e-03 | 1.07e-03 | 40 |
| hsa0522510 | Cervix | CC | Hepatocellular carcinoma | 40/1267 | 168/8465 | 1.52e-03 | 6.39e-03 | 3.78e-03 | 40 |
| hsa05224 | Cervix | CC | Breast cancer | 32/1267 | 147/8465 | 1.66e-02 | 4.88e-02 | 2.88e-02 | 32 |
| hsa0501019 | Cervix | CC | Alzheimer disease | 113/1267 | 384/8465 | 9.67e-14 | 3.92e-12 | 2.32e-12 | 113 |
| hsa0502219 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
| hsa0520517 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
| hsa0436012 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
| hsa0516512 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
| hsa0431012 | Cervix | CC | Wnt signaling pathway | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
| hsa0439013 | Cervix | CC | Hippo signaling pathway | 40/1267 | 157/8465 | 3.64e-04 | 1.82e-03 | 1.07e-03 | 40 |
| hsa0522513 | Cervix | CC | Hepatocellular carcinoma | 40/1267 | 168/8465 | 1.52e-03 | 6.39e-03 | 3.78e-03 | 40 |
| hsa052241 | Cervix | CC | Breast cancer | 32/1267 | 147/8465 | 1.66e-02 | 4.88e-02 | 2.88e-02 | 32 |
| hsa05010 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
| hsa05022 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
| Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| WNT5B | FZD4 | WNT5B_FZD4 | ncWNT | Cervix | CC |
| WNT5B | FZD6 | WNT5B_FZD6 | ncWNT | Cervix | CC |
| WNT5B | FZD1 | WNT5B_FZD1 | ncWNT | CRC | AD |
| WNT5B | FZD4 | WNT5B_FZD4 | ncWNT | CRC | AD |
| WNT5B | FZD5 | WNT5B_FZD5 | ncWNT | CRC | AD |
| WNT5B | FZD4 | WNT5B_FZD4 | ncWNT | CRC | ADJ |
| WNT5B | FZD5 | WNT5B_FZD5 | ncWNT | CRC | ADJ |
| WNT5B | FZD4 | WNT5B_FZD4 | ncWNT | CRC | FAP |
| WNT5B | FZD10 | WNT5B_FZD10 | ncWNT | CRC | MSI-H |
| WNT5B | FZD3 | WNT5B_FZD3 | ncWNT | CRC | MSI-H |
| WNT5B | FZD4 | WNT5B_FZD4 | ncWNT | CRC | MSI-H |
| WNT5B | FZD5 | WNT5B_FZD5 | ncWNT | CRC | MSI-H |
| WNT5B | FZD6 | WNT5B_FZD6 | ncWNT | CRC | MSI-H |
| WNT5B | FZD4 | WNT5B_FZD4 | ncWNT | CRC | SER |
| WNT5B | FZD5 | WNT5B_FZD5 | ncWNT | CRC | SER |
| WNT5B | FZD4 | WNT5B_FZD4 | ncWNT | Endometrium | AEH |
| WNT5B | FZD7 | WNT5B_FZD7 | ncWNT | Endometrium | AEH |
| WNT5B | FZD1 | WNT5B_FZD1 | ncWNT | Esophagus | ESCC |
| WNT5B | FZD10 | WNT5B_FZD10 | ncWNT | Esophagus | ESCC |
| WNT5B | FZD3 | WNT5B_FZD3 | ncWNT | Esophagus | ESCC |
| Page: 1 2 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| WNT5B | SNV | Missense_Mutation | c.26C>T | p.Thr9Met | p.T9M | Q9H1J7 | protein_coding | tolerated(0.13) | benign(0) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| WNT5B | SNV | Missense_Mutation | c.912N>G | p.Cys304Trp | p.C304W | Q9H1J7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C8-A12L-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| WNT5B | SNV | Missense_Mutation | c.67N>A | p.Ala23Thr | p.A23T | Q9H1J7 | protein_coding | tolerated(0.15) | benign(0.011) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| WNT5B | insertion | Frame_Shift_Ins | novel | c.142_143insATAAGACCGTTTCCAGAGCATATGAGGGAAA | p.Cys48TyrfsTer174 | p.C48Yfs*174 | Q9H1J7 | protein_coding | TCGA-BH-A0DP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
| WNT5B | SNV | Missense_Mutation | novel | c.502N>A | p.Gly168Ser | p.G168S | Q9H1J7 | protein_coding | deleterious(0.04) | probably_damaging(0.964) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| WNT5B | SNV | Missense_Mutation | novel | c.994N>C | p.Glu332Gln | p.E332Q | Q9H1J7 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-4J-AA1J-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| WNT5B | SNV | Missense_Mutation | rs749569775 | c.157G>A | p.Gly53Arg | p.G53R | Q9H1J7 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-EK-A2RK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| WNT5B | SNV | Missense_Mutation | c.654A>C | p.Lys218Asn | p.K218N | Q9H1J7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| WNT5B | SNV | Missense_Mutation | rs771391653 | c.824N>T | p.Pro275Leu | p.P275L | Q9H1J7 | protein_coding | tolerated(0.26) | benign(0.046) | TCGA-AU-3779-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| WNT5B | SNV | Missense_Mutation | novel | c.767N>A | p.Arg256His | p.R256H | Q9H1J7 | protein_coding | deleterious(0.01) | probably_damaging(0.951) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 81029 | WNT5B | DRUGGABLE GENOME | Platinum compounds | 24980784 | ||
| 81029 | WNT5B | DRUGGABLE GENOME | fluorouracil | FLUOROURACIL | 23817222 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |